Pangen Biotech

At a glance

Pangen Biotech filed 25 disclosures in the last 12 months, including 3 insider, 3 5% holder and 1 contract. The most recent key filing was on Jun 22.

Revenue for 2025 was ₩13.4B, down 8.6% on 2024. Operating margin was 11.2% against 7% a year earlier. Debt was 9% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩7.7B and operating profit of ₩262.4M.

The 2025 annual report lists 78 employees with an average tenure of 7.1 years and average pay of ₩57.7M, #1086 of 1,829 listed companies by average pay. Its 8 directors and auditors were paid ₩41.7M each on average. It paid no cash dividend for 2025. (주)휴온스 and related parties held 40.72% at year end.

From the 2025 annual report

Staff: 78 (41 men, 37 women), of whom 0 on fixed-term contracts. Total pay for the year: ₩4.4B. Directors and auditors: 8, paid ₩333.9M in total.

No cash dividend was paid for 2025.

Largest shareholder

(주)휴온스 holds 36.67%; with 4 related parties the group holds 40.72% of common shares at year end (from 35.13% at the start of the year).

Auditor: 성현회계법인 · opinion: Unqualified. The report includes an emphasis of matter.

Source: 2025 annual business report (DART). How figures are combined

Financial summary